Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Prazosin [INN:BAN]
RN: 19216-56-9
UNII: XM03YJ541D
InChIKey: IENZQIKPVFGBNW-UHFFFAOYSA-N

Note

  • A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.

Molecular Formula

  • C19-H21-N5-O4

Molecular Weight

  • 383.4059
 

Classification Codes

  • Adrenergic Agents
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Adrenergic Antagonists
  • Antihypertensive Agents
  • Antiviral (COVID-19)
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Neurotransmitter Agents
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Prazosin
  • Prazosin [INN:BAN]

MeSH Heading

  • Prazosin

Synonyms

  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
  • 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
  • 5-25-13-00365 (Beilstein Handbook Reference)
  • BRN 0768345
  • EINECS 242-885-8
  • Furazosin
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-
  • Prazosin
  • Prazosina
  • Prazosina [INN-Spanish]
  • Prazosine
  • Prazosine [INN-French]
  • Prazosinum
  • Prazosinum [INN-Latin]
  • Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-
  • UNII-XM03YJ541D

Systematic Names

  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
  • Prazosin
  • Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-

Registry Numbers

CAS Registry Number

  • 19216-56-9

FDA UNII

  • XM03YJ541D

System Generated Number

  • 0019216569

Structure Descriptors

InChI

InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)

InChIKey

IENZQIKPVFGBNW-UHFFFAOYSA-N

Smiles

COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo oral 280ug/kg (0.28mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 British Medical Journal. Vol. 2, Pg. 508, 1976.
human TDLo oral 1260ug/kg (1.26mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

KIDNEY, URETER, AND BLADDER: OTHER CHANGES 		British Medical Journal. Vol. 1, Pg. 622, 1978.
man TDLo oral 1143ug/kg (1.143mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION Acta Medica Scandinavica. Vol. 213, Pg. 157, 1983.
mouse LD50 intravenous > 400mg/kg (400mg/kg)   Russian Pharmacology and Toxicology Vol. 50, Pg. 182, 1987.
mouse LD50 oral > 4gm/kg (4000mg/kg)   Bollettino Chimico Farmaceutico. Vol. 128, Pg. 129, 1989.
rat LD oral > 3gm/kg (3000mg/kg)   United States Patent Document. Vol. #4734418,
women TDLo oral 20ug/kg (0.02mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION		 Annals of Internal Medicine. Vol. 97, Pg. 455, 1982.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 279 deg C   EXP
log P (octanol-water) 1.280 (none)   EST
Atmospheric OH Rate Constant 2.84E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.